Antitumor activity of Nitronaphthal-NU, a novel mixed-function agent

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Development of novel mixed-function antitumor agents is crucial for cancer therapy.
• Nitronaphthal-NU (Compound 1) was designed based on existing antitumor drug structures.

Purpose of the Study:

• To synthesize and evaluate the antitumor activity and toxicity of Nitronaphthal-NU.
• To compare its efficacy against established and experimental antitumor agents.

Main Methods:

• In vitro cytotoxicity screening in human tumor cell lines (SNB-78, HOP-62, T47D, SiHa).
• In vivo antitumoral potency assessment in murine ascites models (Sarcoma-180, Ehrlich ascites carcinoma).
• Toxicity evaluation including hematological parameters, bone marrow and splenic cellularity, hepatotoxicity, and nephrotoxicity.

Main Results:

• Nitronaphthal-NU exhibited significant in vitro cytotoxicity against lung and CNS cancer cell lines, exceeding CCNU and comparable to Mitonafide.
• In vivo studies demonstrated significant tumor regression and increased median survival times in treated mice compared to controls.
• The compound showed no adverse effects on hematopoiesis, hepatotoxicity, or nephrotoxicity at the optimal dose and inhibited DNA and RNA synthesis in tumor cells.

Conclusions:

• Nitronaphthal-NU is a promising mixed-function antitumor agent with potent efficacy and a favorable toxicity profile.
• Further investigation into Nitronaphthal-NU as a potential cancer therapeutic is warranted.